Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EPAD

Biogen Idec building

Biogen buys into Rodin’s Alzheimer’s candidate

And may acquire the epigenetics-focused Massachusetts firm

EU flag

Public-private partnerships ‘making a difference’ in Europe

One of those is the IMI, which has helped drug development bottlenecks

- PMLiVE

GSK and J&J back new UK dementia discovery fund

Pharma giants collaborate with government to find new treatments

- PMLiVE

Axovant takes Alzheimer’s drug into phase III

Aims to bring first treatment in a decade to market

Is Technology Harming Your Brain?

Is technology harming your brain? Saycomms healthcare PR team confronts different opinions on how technology affects memories and attention span.

Say Communications

- PMLiVE

Counting down to the EFPIA Disclosure Code

Communications director Andy Powrie-Smith on why the Code is part of pharma's 'licence to operate'

UK Life Sciences Strategy - one year on

Genome diagnostic can see if a patient is ‘ageing well’

Test can predict risk of age-related diseases and age of death

- PMLiVE

Amgen and Novartis collaborate on Alzheimer’s research

Will work on the development and commercialisation of BACE inhibitors

- PMLiVE

Industry files complaint against France’s off-label law

Protests against promotion of Roche's Avastin as cheap eye medication

- PMLiVE

EFPIA’s Richard Torbett to move to the ABPI

Will take up commercial role at UK pharma bodyat the end of the month

- PMLiVE

Creating stability with medicines framework

The deals secure stability for both industry and governments

- PMLiVE

Innovative Medicines Initiative appoints executive director

Pierre Meulien joins from Genome Canada 

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links